Armis and Fortinet expand partnership with 8+ security integrations
CalciMedica, Inc. (NASDAQ:CALC), a $43.76 million market cap biotech company, saw Director Eric W. Roberts report purchasing shares of common stock in two transactions on August 28 and August 29, 2025. The purchases totaled $28,531. According to InvestingPro data, the company maintains a strong liquidity position with more cash than debt on its balance sheet.
On August 28, Roberts bought 9,200 shares at a weighted average price of $2.863, with prices ranging from $2.75 to $2.92. The total value of this transaction was $26,340.
On August 29, Roberts bought 800 shares at $2.74 per share, for a total value of $2,191.
Following these transactions, Roberts directly holds 179,706 shares and indirectly holds 356,989 shares by Valence Investments SPV IV, LLC, 66,228 by Valence Investments SPV V, LLC, 316,109 by Valence Investments SPV VI, LLC, 49,894 by Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA, 10,661 by IRA Financial Trust Company CFBO Eric W. Roberts, and 70,907 by FMTC Custodian - Roth IRA FBO Eric W. Roberts.
John Dunn, Esq., Attorney-in-Fact, signed the Form 4 on behalf of Eric W. Roberts on September 2, 2025.
In other recent news, CalciMedica Inc. announced a significant development in its research efforts with the publication of a manuscript in the American Journal of Nephrology. The manuscript details the design and rationale of the Phase 2 KOURAGE trial of Auxora, a treatment for acute kidney injury (AKI) with respiratory failure. Preclinical data from the study showed that Auxora significantly increased the glomerular filtration rate in rat models of AKI. Additionally, a post-hoc analysis from the company’s CARDEA trial indicated a 62.7% relative reduction in mortality among COVID-19 patients with AKI who received Auxora compared to those who received a placebo. In another update, CalciMedica has appointed Baker Tilly US, LLP as its new independent registered public accounting firm following a merger with Moss Adams LLP. The transition was approved by the company’s Board of Directors’ Audit Committee, with no disagreements reported regarding accounting practices or financial disclosures. Moss Adams issued its audit report for the year ending December 31, 2024, without any adverse opinions or modifications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.